Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2016

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2016
Published Aug 10, 2016
70 pages — Published Aug 10, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2016, provides in depth analysis on Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted pipeline therapeutics.

The report provides comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
- The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen

  
Source:
Document ID
GMDHC0447TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Overview71
Therapeutics Development83
  Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Products under Development by Stage of Development81
  Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Products under Development by Therapy Area91
  Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Products under Development by Indication101
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Products under Development by Companies132
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Products under Development by Universities/Institutes152
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Therapeutics Assessment176
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration192
  Assessment by Molecule Type212
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Companies Involved in Therapeutics Development237
  Advaxis, Inc.231
  Aeterna Zentaris Inc.241
  Bavarian Nordic A/S251
  Curevac AG261
  GenSpera, Inc.271
  Inovio Pharmaceuticals, Inc.281
  OncBioMune Pharmaceuticals Inc.291
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Drug Profiles3026
  ADXS-PSA Drug Profile304
  AEZS-120 Drug Profile342
  Cellular Immunotherapy to Target PSA for Prostate Cancer Drug Profile361
  Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer Drug Profile371
  CV-9103 Drug Profile382
  CV-9104 Drug Profile402
  G-114 Drug Profile421
  G-115 Drug Profile431
  INO-5150 Drug Profile441
  Prostatac Drug Profile453
  rilimogene galvacirepvec Drug Profile485
  Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer Drug Profile531
  Vaccine to Target PSA and HMWMAA for Prostate Cancer Drug Profile542
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Dormant Projects561
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Discontinued Products571
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Featured News &Press Releases5811
  Jul 20, 2016: Pre-Clinical Research Supports Additional Studies of OncBioMune Technology for Breast Cancer Vaccine581
  Jul 13, 2016: OncBioMune Submits Protocol to Initiate Phase 2/3 Trial of ProscaVax for Prostate Cancer581
  Jun 14, 2016: OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches591
  Jun 02, 2016: Mexican Regulatory Authorities Supportive of OncBioMunes Phase 2 of ProscaVax for Prostate Cancer591
  May 18, 2016: Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer601
  May 11, 2016: OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer611
  May 04, 2016: OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer621
  Apr 28, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China631
  Apr 12, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Hong Kong631
  Apr 05, 2016: Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts641
  Mar 16, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Europe651
  Feb 23, 2016: OncBioMune Continuing Phase 1 Trial, While Initiating Phase 2 Trial of ProscaVax for Prostate Cancer651
  Dec 16, 2015: FDA Lifts Advaxis Clinical Hold On ADXS-PSA661
  Nov 10, 2015: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China and Ukraine661
  Aug 05, 2015: Advaxis's ADXS-PSA Awarded Research Grants From the Prostate Cancer Foundation and the Movember Foundation672
Appendix692
  Methodology691
  Coverage691
  Secondary Research691
  Primary Research691
  Expert Panel Validation691
  Contact Us691
  Disclaimer701

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Prostate-Specific-Antigen-Gamma-Seminoprotein-or-Kallikrein-3-or-P-30-Antigen-or-Semenogelase-or-KLK3-or-EC-3-4-21-77-Pipeline-Review-H2-2016-2088-16370>
  
APA:
Global Markets Direct - Market Research. (2016). Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Prostate-Specific-Antigen-Gamma-Seminoprotein-or-Kallikrein-3-or-P-30-Antigen-or-Semenogelase-or-KLK3-or-EC-3-4-21-77-Pipeline-Review-H2-2016-2088-16370>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.